Advertisement

Advertisement

SCYX Stock Latest News

Upcoming Stock Splits This Week (June 1 to June 5) – Stay Invested

Market NewsUpcoming Stock Splits This Week (June 1 to June 5) – Stay Invested

Scynexis trading halted, news pending

PremiumThe Fly

Scynexis trading halted, news pending

6d ago

SCYNEXIS Stockholders Approve One-for-Eight Reverse Split

PremiumCompany Announcements

SCYNEXIS Stockholders Approve One-for-Eight Reverse Split

14d ago

Scynexis announces 1-for-8 reverse stock split

PremiumThe Fly

Scynexis announces 1-for-8 reverse stock split

14d ago

Buy Rating Reaffirmed on Scynexis as Rare Disease Pivot and Strong Cash Runway Support Unchanged $4 Price Target

PremiumRatings

Buy Rating Reaffirmed on Scynexis as Rare Disease Pivot and Strong Cash Runway Support Unchanged $4 Price Target

23d ago

Scynexis reports Q1 EPS (42c), consensus (12c)

PremiumThe FlyScynexis reports Q1 EPS (42c), consensus (12c)

24d ago

Scynexis files to sell 87M shares of common stock for holders

The Fly

Scynexis files to sell 87M shares of common stock for holders

1M ago

SCYNEXIS Director Steven Gilman Announces Board Retirement

Company Announcements

SCYNEXIS Director Steven Gilman Announces Board Retirement

2M ago

Scynexis: Strategic Pivot to Rare Disease With ADPKD Asset, Strengthened Balance Sheet, and Antifungal Optionality Support Buy Rating and $4 Target

PremiumRatings

Scynexis: Strategic Pivot to Rare Disease With ADPKD Asset, Strengthened Balance Sheet, and Antifungal Optionality Support Buy Rating and $4 Target

2M ago

SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease

PremiumCompany Announcements

SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease

2M ago

SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline

PremiumCompany Announcements

SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline

2M ago

SCYNEXIS Raises $40 Million in Strategic Private Placement

PremiumCompany Announcements

SCYNEXIS Raises $40 Million in Strategic Private Placement

2M ago

Poxel announces sale of PXL770 to Scynexis for up to $196M

PremiumThe FlyPoxel announces sale of PXL770 to Scynexis for up to $196M

2M ago

Scynexis completes acquisition of PXL-770 for treatment of kidney disease

The Fly

Scynexis completes acquisition of PXL-770 for treatment of kidney disease

2M ago

Scynexis announces $40M private placement

The Fly

Scynexis announces $40M private placement

2M ago

Buy Rating on Scynexis Backed by Strong Cash Runway and Differentiated Next‑Generation Antifungal SCY‑247 Opportunity

PremiumRatings

Buy Rating on Scynexis Backed by Strong Cash Runway and Differentiated Next‑Generation Antifungal SCY‑247 Opportunity

3M ago

Scynexis announces first patients dosed in Phase 1 SAD, MAD trial of SCY-247

PremiumThe Fly

Scynexis announces first patients dosed in Phase 1 SAD, MAD trial of SCY-247

3M ago

Cero Therapeutics appoints Eric Francois to board of directors

PremiumThe Fly

Cero Therapeutics appoints Eric Francois to board of directors

4M ago

Scynexis announces presentation highlighting data from SCY-247

PremiumThe Fly

Scynexis announces presentation highlighting data from SCY-247

4M ago

Scynexis receives U.S. FDA QIDP, Fast Track Designations for SCY-247

PremiumThe FlyScynexis receives U.S. FDA QIDP, Fast Track Designations for SCY-247

4M ago

Scynexis granted 180-day extension by Nasdaq to regain compliance

The Fly

Scynexis granted 180-day extension by Nasdaq to regain compliance

5M ago

SCYNEXIS Halts Phase 3 MARIO Trial, Raising New Questions for Ibrexafungerp’s Growth Path

Company Announcements

SCYNEXIS Halts Phase 3 MARIO Trial, Raising New Questions for Ibrexafungerp’s Growth Path

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >